Matt Gline (L) and Vivek Ramaswamy

Scoop: Vivek Ra­maswamy is hand­ing the CEO job to a top lieu­tenant at Roivant — but he’s not ex­act­ly leav­ing the biotech scene

Over the past 7 years since found­ing Roivant, Vivek Ra­maswamy has been a con­stant blur of biotech build­ing mo­tion.

He launched his first biotech with an Alzheimer’s drug he picked up cheap, and watched the ex­per­i­ment im­plode in one of the high­est pro­file piv­otal dis­as­ters seen in the last decade. But it didn’t slow the 30-some­thing ex­ec down; if any­thing, he hit the ac­cel­er­a­tor. Ra­maswamy blazed glob­al paths and went on to raise bil­lions to spur the cre­ation of a large line­up of lit­tle Vants promis­ing big things at a fast pace. He sold off a sec­tion of the Vant brigade to Sum­it­o­mo Dainip­pon for $3 bil­lion. And more re­cent­ly the re­lent­less deal­mak­er has been build­ing a com­pu­ta­tion­al dis­cov­ery arm to add an AI-dri­ven ap­proach to kick­ing up new pro­grams and com­pa­nies, sup­ple­ment­ing the in-li­cens­ing dri­ve while pur­su­ing ad­vances that have cre­at­ed more than 700 jobs at Roivant, with $2 bil­lion in re­serves.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters